Clinical Trial Update: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression [Phase 3]

View source ↗

Summary

Phase 3 trial investigating RC48-ADC in local advanced or metastatic gastric cancer with HER2 overexpression; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | Phase 3 | Status: UNKNOWN